@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAAx9DQMUosSJrbWuz-pqPSDXHV4-0nX7Kk-7etrHlelo> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAAx9DQMUosSJrbWuz-pqPSDXHV4-0nX7Kk-7etrHlelo#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix mgi: <http://www.informatics.jax.org/marker/MGI:> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix hasAgent: <http://semanticscience.org/resource/SIO_000139> .
@prefix mesh: <http://purl.bioontology.org/ontology/MSH/> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 hasAgent: sub:_2;
    a go:0003824 .
  
  sub:_2 geneProductOf: mgi:2156367;
    a Protein: .
  
  sub:_3 hasAgent: sub:_4;
    a go:0042789 .
  
  sub:_4 geneProductOf: mgi:1859212;
    a Protein: .
  
  sub:_5 occursIn: mesh:D008264, species:10090;
    rdf:object sub:_3;
    rdf:predicate belv:increases;
    rdf:subject sub:_1;
    a rdf:Statement .
  
  sub:assertion rdfs:label "cat(p(MGI:Tlr3)) -> tscript(p(MGI:Irf7))" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_7;
    pav:version "1.4" .
  
  sub:_6 prov:value "From full text: TLRs signal through two main pathways, defined by the adaptor molecules used at the start of each. The best characterized of these is the MyD88-dependent pathway, common to all TLRs except TLR3, which results in rapid activation of the transcription molecules nuclear factor ?B (NF-?B), activator protein 1 and Elk-1 and induction of proinflammatory mediators such as tumour necrosis factor-? (TNF-?), interleukin-6 (IL-6) and cyclooxygenase-2.13,14 Activation of the NF-?B p65 and activator protein 1 transcription factors is reduced in endotoxin-tolerant cells.15 TLR7, -8 and -9 can also induce type I interferon (IFN) production in a MyD88-dependent manner, involving the activation of the interferon regulatory factor 5 (IRF-5)16 and IRF-717 transcription factors. The second, less well-studied pathway is thought to be limited to TLR3 and TLR4. TLR signalling via the adaptor molecules Toll/IL-1-receptor-domain-containing adaptor inducing IFN-? (TRIF) and TRIF-related adaptor molecule (TRAM) activates IRF-3 and IRF-7 and, ultimately, IFN-inducible genes such as IFN-?-inducible protein 10 (IP-10) and RANTES, via type I IFN production and autocrine activation of the JAK/STAT pathway";
    prov:wasQuotedFrom pubmed:17034424 .
  
  sub:_7 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:17034424;
    prov:wasDerivedFrom beldoc:, sub:_6 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:30:46.640+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}